Survival of TNF-alpha antagonists in rheumatoid arthritis: A long-term study

Clinical and Experimental Rheumatology

Volumn 30, Issue 1, 2012, Pages 31-38

  Markatseli, Theodora E ^a   Alamanos, Yannis ^b   Saougou, Ioanna ^a   Voulgari, Paraskevi V ^a   Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Rheumatoid arthritis; TNF antagonists

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOGLOBULIN M; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; INFECTION; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863760529     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. BRENNAN FM, MAINI RN, FELDMANN M. TNF-α pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31: 293-8.
2. FELDMANN M, BRENNAN FM, MALNL RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440.
3. VAN DER HEIDE A, JACOBS JW, BIJLSMA JW et al. The effectiveness of early treatment with " second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996; 124: 699-707.
4. VAN JAARSVELD CH, JACOBS JW, VAN DER VEEN MJ et al. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, the Netherlands. Ann Rheum Dis 2000; 59: 468-77.
5. NEWSOME G. for the American College of Rheumatology. Guidelines for the management of rheumatoid arthritis: 2002 Update. Am Acad Nurse Pract 2002; 14: 432-7.
6. MAKINEN H, KAUTIAINEN H, HANNONEN P et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007; 34: 316-21.
7. RANTALAIHO V, KORPELA M, LAASONEN L et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 2010; 12: R122.
8. FURST DE, BREEDVELD FC, KALDEN JR et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis 2003; 62 (Suppl. 2): ii2-9.
9. VAN DER HEIJDE D, KLARESKOG L, LANDEWÉ R et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 3928-39.
10. EMERY P, BREEDVELD FC, HALL S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82.
11. WESTHOVENS R, YOCUM D, HAN J et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities. A large, randomized, placebo controlled trial. Arthritis Rheum 2006; 54: 1075-86.
12. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
13. VOULGARI PV, ALAMANOS Y, NIKAS SN, BOUGIAS DV, TEMEKONIDIS TI, DROSOS AA. Infliximab therapy in established rheumatoid arthritis: An observational study. Am J Med 2005; 118: 515-20.
14. LIN J, ZIRING D, DESAI S et al. TNF alpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008; 126: 13-30.
15. EXARCHOU SA, VOULGARI PV, MARKATSELI TE, ZIOGA A, DROSOS AA. Immunemediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009; 38: 328-31.
16. ARNETT FC, EDWORTHY SM, BLOCH DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
17. PREVOO ML, VAN 'T HOF MA, KUPER HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
18. GARTLEHNER G, HANSEN RA, JONAS BL, THIEDA P, LOHR KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006; 33: 2398-408.
19. ALONSO-RUIZ A, PIJOAN JI, ANSUATEGUI E, URKAREGI A, CALABOZO M, QUINTANA A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskeletal Disorders 2008; 9: 52.
20. LEE YH, WOO JH, RHO YH, CHOI SJ, JI JD, SONG GG. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int 2008; 28: 553-9.
21. DONAHUE KE, GARTLEHNER G, JONAS DE et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148: 124-34.
22. FURST DE, SCHIFF MH, FLEISCHMANN RM et al. Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563-71.
23. VAN DE PUTTE LB, ATKINS C, MALAISE M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508-16.
24. VAN DER HEIJDE D, KLARESKOG L, LANDEWÉ R et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 3928-39.
25. KEANE J, GERSHON S, WISE RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha - neutralizing agent. N Engl J Med 2001; 345: 1098-104.
26. HOCHBERG MC, TRACY JK, HAWKINS-HOLT M, FLORES RH. Comparison of the efficacy of the tumor necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003; 62 (Suppl. 2): ii13-6.
27. KRISTENSEN LE, SAXNE T, GEBOREK P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006; 54: 600-6.
28. GEBOREK P, CRNKIC M, PETERSSON IF, SAXNE T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-8.
29. KIEVIT W, ADANG EM, FRANSEN J et al. The effectiveness and medication costs of three anti-tumor necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008; 67: 1229-34.
30. DU PAN SM, DEHLER S, CIUREA A, ZISWILER HR, GABAY C, FINCKH A. SWISS CLINICAL QUALITY MANAGEMENT PHYSICIANS: Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009; 61: 560-8.
31. HETLAND ML, CHRISTENSEN IJ, TARP U et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
32. VOULGARI PV, ALAMANOS Y, DROSOS AA. Persistent clinical response of infliximab therapy in patients with refractory rheumatoid arthritis, over a 3-year period. Cur Clin Pharmacol 2006; 1: 103-8.
33. CRUYSSEN BV, DUREZ P, WESTHOVENS R, DE KEYSER F. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity. Arthritis Res Ther 2010; 12: R77.
34. WOLBINK GJ, VIS M, LEMS W et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-5.
35. BARTELDS GM, WIJBRANDTS CA, NURMOHAMED MT et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
36. KRISTENSEN LE, SAXNE T, NILSSON JA, GEBOREK P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis: results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006; 8: R174.
37. TEMEKONIDIS TI, GEORGIADIS AN, ALAMANOS Y, BOUGIAS DV, VOULGARI PV, DROSOS AA. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis 2002; 61: 822-5.
38. FERRACCIOLI GF, ASSALONI R, DI POI E, GREMESE E, DE MARCHI G, FABRIS M. Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial. Rheumatology 2002; 41: 1109-12.
39. VERSTAPPEN SMM, JACOBS JWG, VAN DER VEEN MJ et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-9.
40. HETLAND ML, STENGAARD-PEDERSEN K, JUNKER P et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis; An investigatorinitiated, multicenter, randomized, doubleblind, parallel-group, placebo-controlled study. Arthritis Rheum 2006; 54: 1401-9.
41. CHOY EH, SMITH CM, FAREWELL V et al. FOR THE CARDERA (COMBINATION ANTI-RHEUMATIC DRUGS IN EARLY RHEUMATOID ARHRITIS) TRIAL GROUP: Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 2008; 67: 656-63.